Long-term effects of insulin glargine on the risk of breast cancer

Diabetologia

Volumn 54, Issue 9, 2011, Pages 2254-2262

  Suissa, S ^a,b   Azoulay, L ^a,b   Dell'Aniello, S ^a   Evans, M ^c   Vora, J ^d   Pollak, M ^b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c LLANDOUGH HOSPITAL   (United Kingdom)

^d ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Carcinogenicity; Cohort studies; Drug safety; Insulin analogues; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIPHASIC INSULIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN GLARGINE; LONG ACTING INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT;

AGED; BREAST NEOPLASMS; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN, LONG-ACTING; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME;

EID: 80054700909     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-011-2190-9     Document Type: Article

References (35)

1. Werner H, Weinstein D, Bentov I (2008) Similarities and differences between insulin and IGF-I: structures, receptors, and signalling pathways. Arch Physiol Biochem 114:17-22 (Pubitemid 351998748)
2. Kurtzhals P, Schaffer L, Sorensen A et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999-1005 (Pubitemid 30349423)
3. Sommerfeld MR, Muller G, Tschank G et al (2010) In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PLoS ONE 5:e9540
4. Baserga R (1999) The IGF-I receptor in cancer research. Exp Cell Res 253:1-6
5. Mayer D, Chantelau E (2010) Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells. Arch Physiol Biochem 116:73-78
6. Hemkens LG, Grouven U, Bender R et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52:1732-1744
7. Colhoun HM (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52:1755-1765
8. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G (2009) Insulin glargine use and short-term incidence of malignancies: a population-based follow-up study in Sweden. Diabetologia 52:1745-1754
9. Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766-1777
10. Mannucci E, Monami M, Balzi D et al (2010) Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 33:1997-2003
11. Pocock SJ, Smeeth L (2009) Insulin glargine and malignancy: an unwarranted alarm. Lancet 374:511-513
12. Hernandez-Diaz S, Adami HO (2010) Diabetes therapy and cancer risk: causal effects and other plausible explanations. Diabetologia 53:802-808
13. US Department of Health & Human Services. Early communication about safety of Lantus (insulin glargine).MedWatch The FDA Safety Information and Adverse Event Reporting Program (July 1, 2009).www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm169722.htm. Accessed 3 May 2011.
14. European Medicines Agency update on safety of insulin glargine. European Medicines Agency (July 23, 2009). www.ema.europa.eu/docs/en-GB/document-library/ Press-release/2009/11/WC500010016.pdf. Accessed 3 May 2011.
15. American Diabetes Association. Statement from the American Diabetes Association Related to Studies Published in 'Diabetologia'. NeLM news service (June 26, 2009). http://www.diabetes.org/for-media/2009/statement-from-the- american-2009-1.html. Accessed 3 May 2011.
16. Home PD, Lagarenne P (2009) Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 52:2499-2506
17. Hemkens LG, Grouven U, Bender R, Sawicki PT (2010) Insufficient evaluation of adverse events is not a proof of safety. Diabetologia 53:790-792
18. Walley T, Mantgani A (1997) The UK General Practice Research Database. Lancet 350:1097-1099 (Pubitemid 27437871)
19. Opatrny L, Dell'Aniello S, Assouline S, Suissa S (2008) Hormone replacement therapy use and variations in the risk of breast cancer. BJOG 115:169-175 (Pubitemid 350233601)
20. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR (2010) Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33:1304-1308
21. Heinzl H, Kaider A, Zlabinger G (1996) Assessing interactions of binary time-dependent covariates with time in cox proportional hazards regression models using cubic spline functions. Stat Med 15:2589-2601 (Pubitemid 26413815)
22. Yehezkel E, Weinstein D, Simon M, Sarfstein R, Laron Z, Werner H (2010) Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor. Diabetologia 53:2667-2675
23. Law JH, Habibi G, Hu K et al (2008) Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68:10238-10246
24. Cox ME, Gleave ME, Zakikhani M et al (2009) Insulin receptor expression by human prostate cancers. Prostate 69:33-40
25. Lambe M, Hsieh C, Trichopoulos D, Ekbom A, Pavia M, Adami HO (1994) Transient increase in the risk of breast cancer after giving birth. N Engl J Med 331:5-9 (Pubitemid 24195593)
26. Welch HG, Black WC (1997) Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med 127:1023-1028 (Pubitemid 27516615)
27. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915-928
28. Hansen BF, Danielsen GM, Drejer K et al (1996) Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 315:271-279 (Pubitemid 26113562)
29. Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, Mayer D (2009) Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer 16:429-441
30. Jorgensen L, Dideriksen L, Drejen K (1992) Carcinogenic effect of human insulin and B10Asp in female rats. Diabetologia 35 (Suppl 1):A3
31. Brange J, Ribel U, Hansen JF et al (1988) Monomeric insulins obtained by protein engineering and their medical implications. Nature 333:679-682
32. Dejgaard A, Lynggaard H, Rastam J, Krogsgaard TM (2009) No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia 52:2507-2512
33. Michels KB, Solomon CG, Hu FB et al (2003) Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care 26:1752-1758 (Pubitemid 36929115)
34. Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H (2009) Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 180:385-397
35. Horvath K, Jeitler K, Berghold A et al. Long-acting insulin analogues vs NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007, Issue 2. Art. No.: CD005613. doi:10.1002/14651858. CD005613.pub3 (Pubitemid 351805825)